Harbour BioMed Announces 2023 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ — Harbour BioMed (“HBM”, or the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced its interim results for the six months ended June 30, 2023. Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed commented, “In the first half of 2023, Harbour BioMed recorded a significant increase in its revenue, turning losses into profits. The outstanding performance demonstrated the Company’s excellent global business development capabilities and remarkable achievements in cost reduction and efficiency improvement. Our strategy on global innovation ensures we maintain a competitive edge in multiple fields of drug discovery, further creating favorable advantages for differentiated pipeline development and expansive international collaborations, thus unleashing a wider range of value. Despite the numerous challenges ahead, we will steadfastly promote the Company’s global strategy to drive sustainable growth on the base of innovation, thereby accelerating the advancement of our business.” With strong R&D capabilities, the Company has continued to optimize and upgrade its industry leading and globally patented antibody platforms to further implement its “Antibody+” business strategy. During the reporting period, the Company filed 268 patents, 12 of which had been granted invention patents by the China National Intellectual Property Administration with 174 in progress. Robust patent clusters provide effective protection for the Company’s products and new technology innovations, enabling the company to maintain an advantageous position in global biotech industry. Leveraging the unique antibody discovery technology, Harbour Therapeutics currently has over 10 innovative global programs in immuno-oncology and immunology, while Nona Biosciences further create value through global collaborations based on technology innovations. The Company has achieved positive half-yearly revenue growth rates exceeding 40% for two consecutive years benefiting from its robust technology platform and cutting edge innovations in the field of Immuno-oncology and Immunology. The Company recorded revenues of over $40 million in the first half of 2023 and achieved its first interim profit of approximately $3 million. Turning to a profit verifies Harbour BioMed’s sustained and outstanding value creation ability. The out-licensing and collaboration of innovative products from Harbour Therapeutics’ portfolio, including HBM7008 and batoclimab (HBM9161), have significantly contributed to this growth. At the same time, the Company has also seen the positive contribution from Nona Biosciences to the earnings growth and profits during the period. Harbour Therapeutics: Advanced pipeline with exciting advancements Batoclimab (HBM9161) ‘s positive results on its phase III clinical trial for the treatment of generalized myasthenia gravis (gMG) were announced during 1H2023. Batoclimab resulted in a higher rate of sustained MG-ADL improvement in adult patients with gMG than placebo, and sustained improvement were observed in the second cycle. As the most advanced asset in the portfolio, this marks a major milestone for Harbour BioMed as it is the first positive readout of a registrational trial since its establishment. Also, as the first anti-FcRn product with a complete data set in Greater China, this result of batoclimab has significant positive impact on the development of effective therapeutics for patients with gMG in China. Porustobart (HBM4003) is a next-generation fully human heavy chain only anti-CTLA-4 antibody generated from the Harbour Mice® HCAb platform. It has showcased promising efficacy and safety profile in multiple clinical trials in patients with melanoma, neuroendocrine neoplasms and hepatocellular carcinoma, demonstrating the potential to be developed as a cornerstone therapy in immuno-oncology. Data released in 1H2023 showed that the overall objective response rate (ORR) was 36.8% in its phase Ib clinical trial of porustobart in combination with toripalimab in patients with advanced high-grade neuroendocrine neoplasms, and in its phase Ib clinical trial of porustobart in combination with toripalimab in patients with hepatocellular carcinoma, the ORR hit 46.7%. The Company is poised for the first pivotal trial of porustobart in the next 6 months and plans to expand in multiple new indications including colorectal cancer. HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. It obtained U.S. FDA clearance for phase I trial in January 2023 and completed the first patient dosing in June 2023. As a newly discovered member of the B7 family, B7H7/HHLA2 expression is found non-overlapping with PD-L1 expression in multiple tumor types, which indicates an alternative immune evasion pathway besides PD-(L)1. Preclinical data demonstrated its immune activation and anti-tumor functional activities, showing great potential to address huge unmet medical needs in patients with advanced malignancies. HBM9033 is an antibody-drug conjugate-based (ADC) drug that specifically targets human mesothelin (MSLN), a TAA that is upregulated in various solid tumors, including mesothelioma, ovary cancer, lung cancer, breast cancer, and pancreatic cancers. HBM9033 is the first ADC product of the Company, which is generated from the Company’s patented ADC platform and has obtained the IND Clearance by U.S. FDA for phase I trial in August 2023. The collaboration with industry partners on product development has provided more diversified avenues and enriched resources for Harbour Therapeutics’ portfolio advancement, which is an integral part of the strategy that the Company will continue to implement and optimize. Regional and global business collaborations are accelerating the development of numerous programs including HBM7022, HBM7008 and HBM9378. These efforts have verified our innovation ability and recognized the value of the product portfolio of the Company. Nona Biosciences: Unleashing platform value to shape the second growth curve As a pioneer in innovative antibody platform technology, the Company continues to advance the “Antibody+” strategy based on its unique advantages of Harbour Mice® technology and develop its strengths in cutting-edge research areas such as bispecific antibody, ADC, mRNA, CAR-T, artificial intelligence and protein engineering, providing strong momentum for breakthroughs in innovative technologies. Nona Biosciences, a wholly-owned subsidiary of the Company, as a pivot of value realization and business expansion, is committed to providing global partners with innovative antibody solutions, continuously developing the global cooperation network, and constantly exploring diverse business areas to promote sustainable business growth. With its world-leading technology innovation, the Company’s second growth curve is steadily gaining

COVID-19 virus is evolving rapidly in white-tailed deer

White-tailed deer across Ohio have been infected with the virus that causes COVID-19, new research has found – and the results also show that viral variants evolve about three times faster in deer than in humans. Scientists collected 1,522 nasal swabs from free-ranging deer in 83 of the state’s 88 counties between November 2021 and March 2022. More than 10% of the samples were positive for the SARS-CoV-2 virus, and at least one positive case was found in 59% of the counties in which testing took place. Genomic analysis showed that at least 30 infections in deer had been introduced by humans – a figure that surprised the research team. “We generally talk about interspecies transmission as a rare event, but this wasn’t a huge sampling, and we’re able to document 30 spillovers. It seems to be moving between people and animals quite easily,” said Andrew Bowman, associate professor of veterinary preventive medicine at The Ohio State University and co-senior author of the study. “And the evidence is growing that humans can get it from deer – which isn’t radically surprising. It’s probably not a one-way pipeline.” The combined findings suggest that the white-tailed deer species is a reservoir for SARS-CoV-2 that enables continuing mutation, and that the virus’s circulation in deer could lead to its spread to other wildlife and livestock. The study is published today in Nature Communications. Bowman and colleagues previously reported detection of SARS-CoV-2 infections in white-tailed deer in nine Ohio locations in December 2021, and are continuing to monitor deer for infection by more recent variants. “We expanded across Ohio to see if this was a localized problem – and we find it in lots of places, so it’s not just a localized event,” Bowman said. “Some of the thought back then was that maybe it’s just in urban deer because they’re in closer contact with people. But in rural parts of the state, we’re finding plenty of positive deer.” Beyond the detection of active infections, researchers also found through blood samples containing antibodies – indicating previous exposure to the virus – that an estimated 23.5% of deer in Ohio had been infected at one time or another. The 80 whole-genome sequences obtained from the collected samples were represented groups of viral variants: the highly contagious delta variant, the predominant human strain in the United States in the early fall of 2021 that accounted for almost 90% of the sequences, and alpha, the first named variant of concern that had circulated in humans in the spring of 2021. The analysis revealed that the genetic composition of delta variants in deer matched dominant lineages found in humans at the time, pointing to the spillover events, and that deer-to-deer transmission followed in clusters, some spanning multiple counties. “There’s probably a timing component to what we found – we were near the end of a delta peak in humans, and then we see a lot of delta in deer,” Bowman said. “But we were well past the last alpha detection in humans. So the idea that deer are holding onto lineages that have since gone extinct in humans is something we were worried about.” The study did suggest that COVID-19 vaccination is likely to help protect people against severe disease in the event of a spillover back to humans. An analysis of the effects of deer variants on Siberian hamsters, an animal model for SARS-CoV-2 studies, showed that vaccinated hamsters did not get as sick from infection as unvaccinated animals. That said, the variants circulating in deer are expected to continue to change. An investigation of the mutations found in the samples provided evidence of more rapid evolution of both alpha and delta variants in deer compared to humans. “Not only are deer getting infected with and maintaining SARS-CoV-2, but the rate of change is accelerated in deer – potentially away from what has infected humans,” Bowman said. How the virus is transmitted from humans to white-tailed deer remains a mystery. And so far, even with about 30 million free-ranging deer in the U.S., no substantial outbreaks of deer-origin strains have occurred in humans. Circulation among animals, however, remains highly likely. Bowman noted that about 70% of free-ranging deer in Ohio have not been infected or exposed to the virus, “so that’s a large body of naive animals that the virus could spread through rather uninhibited.” “Having that animal host in play creates things we need to watch out for,” he said. “If this trajectory continues for years and we have a virus that becomes deer-adapted, then does that become the pathway into other animal hosts, wildlife or domestic? We just don’t know.” This work was supported by the National Institute of Allergy and Infectious Diseases and Ohio State’s Infectious Diseases Institute. Martha Nelson of the National Library of Medicine was co-corresponding author of the study. Ohio State co-authors Dillon McBride, Steven Overend, Devra Huey, Amanda Williams, Seth Faith and Jacqueline Nolting worked on the study with co-authors from St. Jude Children’s Research Hospital; the University of California, Los Angeles; the National Research Centre in Giza, Egypt; PathAI Diagnostics; the Ohio Department of Natural Resources; the U.S. Department of Agriculture; Columbus and Franklin County Metroparks; and the Rega Institute for Medical Research in Belgium.

Lungs as We’ve Never Published Them Before

To show the long-term effects of severe Covid on the lungs, the Graphics desk created visual renderings based on data from CT scans. Times Insider explains who we are and what we do, and delivers behind-the-scenes insights into how our journalism comes together. Marlene Rodríguez used an inhaler to help her walk up the stairs. In his backyard, Andy Muñoz hefted his oxygen machine onto his lap to sit on a swing beside his son. Tom Kennedy brought his machine to the golf course. All of these patients were suffering from the lasting effects of severe Covid-19 infections. Signs of their lung damage — frequent breaks during previously easy activities, a clear tube tucked under the nose and behind the ears — were evident. But what was visible was only part of the story. Severe Covid cases often leave behind a hidden map of destruction, along with indications of the body’s attempts to heal. To show these effects, a recent project from the Graphics and Science desks at The New York Times looked inside the human body in a way no other Times article had before. Using data from CT scans, The Times constructed 3-D models of three patients’ lungs. The approach was inspired by a technique known as cinematic rendering, which is used by doctors to visualize organs, tissue and bones. Published in Monday’s newspaper, the renderings show the signs of limited lung function in Ms. Rodríguez, 32; Mr. Muñoz, 36; and Mr. Kennedy, 59, months after their infections. Andy Muñoz, 36, spent months in intensive care with Covid pneumonia.Meridith Kohut for The New York Times “Our job is to make things visible,” said Simone Landon, a deputy graphics editor who oversaw the project. “We knew people got really sick. We’d done a ton of reporting on the strain on hospitals and patients, and how painful and awful the disease could be. But we had not been able to show the actual damage to the body.” The project began last year when Noah Bassetti-Blum, then a Graphics editor at The Times (he left the company in January 2023), became familiar with cinematic rendering and wanted to apply the technique to a story dealing with Covid “sequelae,” or conditions that result from a previous disease or injury. The Graphics desk reached out to Pam Belluck, a health and science reporter whom Mr. Bassetti-Blum referred to as “the poet and the professional when it comes to working with patients with long-term health issues.” Ms. Belluck knew that the effects of Covid’s sequelae in the body were often frustratingly hard to see, so she suggested that the team focus on the lungs, as damage in the lungs is apparent to doctors in CT scans. But, to most people, a CT scan can feel abstract and nebulous. Cinematic renderings take those scans and make the extent of the damage painfully clear. Tom Kennedy, 59, hit golf balls with his wife, Gayle, and a friend in Houston in March.Meridith Kohut for The New York Times Ms. Belluck and the team decided that profiling a few patients and tracing their history with Covid would supplement the use of 3-D graphics. With the help of physicians at several hospitals, the team selected three patients who were hospitalized with Covid early in the pandemic and who consented to share their medical records. The patients’ lungs resembled scarred battlefields — tissue had retreated or had grown inflamed, and large cavities had opened up. But their lungs also showed signs of healing over time, appearing less shriveled and closer to normal size. The Times wanted to create two sets of models of the patients’ lungs: one from scans taken right after they were infected and a second from later scans that showed their lungs healing. Initially, the team planned to partner with an outside organization that could complete the cinematic rendering. But Jeremy White, a graphics editor, thought it could be done in-house. He used Maya, a software program, to create 3-D images from the patients’ CT scans. Marlene Rodríguez’s children love the trampoline, but she couldn’t bounce with them for long before her oxygen saturation dropped.Meridith Kohut for The New York Times In the past, 3-D representations of organs that appeared in Times articles had been based on generic stand-ins. Mr. White’s graphics are custom representations of the respiratory systems described in the article. “We’re visualizing medical data in a way we haven’t before,” he said. And while these 3-D models demonstrate a new capability in the newsroom, Ms. Belluck said they were enhanced by the experiences of the patients. She spent hours interviewing Mr. Kennedy, Mr. Muñoz, Ms. Rodríguez and their doctors. The Times assigned the photographer Meridith Kohut to visit the patients at home; her pictures show them at the dinner table and playing with their children while aided by oxygen tubes. Ms. Belluck said she hoped the article might help readers understand more about the long-term effects that can stem from Covid. “The human stories really reach people,” she said.

Runners raced through mud in California. Now some have rashes and fevers.

For hours, Noa Umbaugh and her five friends ran, crawled and dragged one another through a gritty obstacle course at the Sonoma Raceway in Sonoma, Calif. Tangles of barbed wire and rows of wooden boards forced them to submerge themselves in pits of muddy water. It was all part of the appeal of the 10-kilometer race put on by Tough Mudder, a race organizer that boasts about the grimy challenge of its obstacle courses. Umbaugh and her friends celebrated after completing the course on Aug. 20. They washed off the mud and went home. But the next morning, Umbaugh woke up and discovered a rash of painful red bumps covering her legs and stomach. They were sore and hot to the touch. Her friends had them, too. Her concerns grew when she found more stories on social media of other Tough Mudder participants coming down with similar symptoms. “It was just disgusting,” Umbaugh, 26, told The Washington Post. A doctor diagnosed Umbaugh with folliculitis, a skin infection sometimes caused by bacteria, and prescribed antibiotics. An announcement from the Sonoma County Department of Health Services later that week said she wasn’t alone: Multiple participants had reported rashes accompanied by fevers, muscle pain and vomiting after running the Tough Mudder race, it warned in a public health advisory. Tough Mudder, the Sonoma Raceway and the Sonoma County Department of Health Services did not immediately respond to requests for comment Sunday evening. Umbaugh was running her second Tough Mudder race after first completing a course the previous year, also at the Sonoma Raceway. The event, which featured several obstacle courses of different lengths over the weekend, felt like a fun challenge to her and her group of friends, an outdoorsy hiking group. Nothing seemed amiss until the day after, when Umbaugh woke up with a rash. She feared that small cuts she had gotten on her knees while climbing around rocks on the obstacle course may have contributed to the infection. Share this articleShare “I looked in the mirror, and my entire knees were covered, my legs were covered, my stomach, too,” Umbaugh said. “It was like something I’ve never seen before.” She quickly found that she wasn’t the only one. Increasingly alarmed posts on the Tough Mudder subreddit, a forum for the race’s participants, described runners visiting the emergency room and receiving diagnoses for bacterial infections. Umbaugh was prescribed antibiotics but did not get her condition tested to identify the bacteria responsible for her infection, she said. A Sonoma County official said they have confirmed at least 15 cases of people experiencing symptoms after the race, the Santa Rosa Press Democrat reported Wednesday. Some participants exhibited symptoms consistent with a bacterial infection, and one patient tested positive for Aeromonas, a waterborne bacteria. Tough Mudder acknowledged the reports of infections and said in a message to participants sent after the Sonoma County health alert that it was investigating the incident, Umbaugh said, but the company did not respond to her request for a refund for the race’s $150 entrance fee. Umbaugh is concerned about whether organizers tested the site, which she said is grazed by animals. The Sonoma Raceway uses a herd of sheep to manage its grassland, according to the raceway’s website. Sonoma Raceway did not immediately respond to an inquiry about whether animals grazed the fields where the Tough Mudder races took place. One week later, Umbaugh’s rash has lessened but not disappeared entirely, she said. She is considering checking with her doctor again. She and her friends spent the week nervously updating each other on their symptoms. They will opt for a hike instead of a mud-soaked obstacle course the next time they get together. “I wanted to try it out,” Umbaugh said. “But I’ll never do it again.”

Recurrent urinary tract infections led to the diagnosis of cross-renal ectopia: A case report.

Crossed renal ectopy (CRE) is a very rare congenital kidney anomaly. CRE is usually asymptomatic and is most often discovered incidentally, but the patient may sometimes develop various renal manifestations.We report a case of a girl who was symptomatic of several episodes of urinary tract infections and whose investigations including ultrasound, uroscan, renal scan and voiding cystourethrogram concluded that she had a crossed left renal ectopy without vesico-ureteral reflux. A regular Follow-up revealed no further symptoms or complications, with partial resolution of the hydronephrosis, and no recurrence of urinary tract infections after hygienic rules. This case didn’t require surgical intervention.CRE is an infrequently occurring congenital malformation. Uroscan is an excellent tool to describe the full anatomical details of this pathology; and the information provided is crucial for surgeons, nephrologists, and radiologists to aid in the proper handling of this pathology.CRE is a rare disease that can be diagnosed incidentally. Treatment is only indicated if complications occur or if there is other associated renal disease. Patients require continuous follow-up and need to be examined for potential complications.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Hydrocephalus Shunts Market 2023 Current Scenario, Segmentation, Future Prospects and Forecast Outlook 2031

The global hydrocephalus shunts market was valued at $291.00 million in 2019 and is projected to reach $322.01 million by 2027, registering a CAGR of 2.8% from 2020 to 2027. Growth in the number of hydrocephalic patients across the world majorly drives the growth of the hydrocephalus shunts market. For instance, according to the National Institute of Neurological Disorders and Stroke, in 2020, 1 to 2 of every 1000 babies are born with hydrocephalus, globally. Thus, considering the total number of newborns per year, the prevalence of hydrocephalus is all set to increase in the future. Furthermore, a rise in cases of neurological disorders, owing to congenital abnormalities and lifestyle diseases as well as a rise in incidences of brain and nerve injuries, boosts the demand for hydrocephalic shunts. In addition, the use of advanced programmable valves helps neurosurgeons to externally adjust valve pressure used in shunts during the treatment. Hydrocephalus is a neurological disorder caused due to abnormal accumulation of cerebrospinal fluid or CSF in the brain cavities called ventricles. The human body produces approximately 500 ml of CSF on daily basis, with the continuous replacement of the fluid as it is reabsorbed. In normal conditions, there is a subtle balance in between the amount of fluid produced and the rate at which it is absorbed within the body. Hydrocephalus occurs when there is a disruption in this balance. As ventricles produce CSF continuously, this disruption results in the accumulation of fluid, causing ventricles to enlarge and increase pressure on the brain tissues. Download Free Sample of This Strategic Report: https://reportocean.com/industry-verticals/sample-request?report_id=AMR1319 This thereby helps in controlling over-draining and under-draining issues associated with fixed pressure valves, which, in turn, is expected to drive the growth of the hydrocephalic shunts market. In addition, the use of programmable valves in treating hydrocephalus is anticipated to gain popularity in the coming years as most the medical professionals are opting for programmable shunts to reduce infections and malfunctions caused due to repetitive shunt surgeries. However, serious damages caused by infections and malfunctions of existing shunts greatly limit market growth. Some deleterious complications include irreversible brain injuries, meningitis, endocarditis, traumatic perforation, tricuspid regurgitation, heart failure, pulmonary hypertension, and others. On the contrary, advancements in shunt technology for reducing shunt complications are projected to create lucrative opportunities for market growth. This condition is commonly treated by surgical procedures, performed by neurosurgeons, which involves implanting a tube “shunt” into the human brain. This shunt is responsible for channeling and diverting the fluid from ventricles to other parts of the body, wherein it can be reabsorbed and transported back to the bloodstream. Surgical procedure controls hydrocephalus in most patients, however, implanting a shunt does not cure the condition. It is a life-long disorder, accompanied by several long-term complications. Moreover, if these complications are left untreated or undiagnosed, they cause severe brain damages and could be life-threatening. The global hydrocephalus shunts market is segmented on the basis of type, age group, and region. By type, the market is classified into ventriculo-peritoneal shunts, ventriculo-atrial shunts, ventriculo-pleural shunts, and lumbo-peritoneal shunts. By age group, the hydrocephalus shunts market is categorized into infants, children, and adults. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The healthcare sector is vital to both national economies and people all across the world. One of the industries with the fastest growth rates is this one. There is a correlation between income levels and healthcare spending across nations because healthcare spending accounts for more than 10% of the GDP of the majority of developed countries. According to the Centers for Medicare and Medicaid Services, US healthcare spending increased by 4.6% in 2019 to reach US$ 3.8 trillion, or US$ 11,582 per person and represented 17.7% of GDP. Additionally, households paid for 28.4% of all health expenditures, followed by the federal government for 29.0%. 16.1% of all healthcare costs were paid for by state and municipal governments, while 7.5% came from other private sources. Download Free Sample of This Strategic Report: https://reportocean.com/industry-verticals/sample-request?report_id=AMR1319 Due to advancements spurred by AI/ML, the impact of digital health technology will grow. Data from the Department for Promotion of Industry and Internal Trade show that FDI in the medicines and medication sector totaled US$19.12 billion (DPIIT). KEY BENEFITS FOR STAKEHOLDERS ? This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2027, which assists to identify the prevailing market opportunities.? An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.? A comprehensive analysis of the factors that drive and restrain the growth of the global hydrocephalus shunt market is provided.? An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves. KEY MARKET PLAYERS– Christoph Miethke GmbH & Co. KG– G. Surgiwear Ltd.– HLL Lifecare Limited– HpBio Prteses, Inc.– Integra Life Sciences– Kaneka Medix Corporation– Medtronic plc– Natus Medical Incorporated– Spiegelberg GmbH & CO. KG– Tokibo Co., Ltd. KEY MARKET SEGMENTS– By Typeo Ventriculo-peritonealo Ventriculo-atrialo Ventriculo-pleuralo Lumbo-peritoneal You Can Browse The Request Full Report here: https://reportocean.com/industry-verticals/sample-request?report_id=AMR1319 – By Age Groupo Infantso Childreno Adults – By Regiono North America? U.S.? Canada? Mexicoo Europe? Germany? UK? France? Italy? Spain? Rest of Europeo Asia-Pacific? Japan? China? India? Australia? South Korea? Rest of Asia-Pacifico LAMEA? Brazil? Saudi Arabia? South Africa? Rest of LAMEA Table of Content: Report Overview Global Growth Trends Competition Landscape by Key Players Data Segments North America Market Analysis Europe Market Analysis Asia-Pacific Market Analysis Latin America Market Analysis Middle East & Africa Market Analysis Key Players Profiles Market Analysis Analysts Viewpoints/Conclusions Appendix Reasons to Buy This Report: This file will help the peruses with appreciation the opposition interior the ventures and structures for the serious local weather to improve the feasible benefit. The document moreover facilities round the cutthroat scene of the market, and provides exhaustively the piece of the pie, industry positioning, contender organic system, market execution, new object advancement,

Bone Grafts and Substitutes Market Unlocking Potential: Share, Size, Segmentation Analysis, Key Segments, and Forecast 2031

The global bone grafts & substitutes market was valued at $2,652.6 million in 2020, and is projected to reach $3,362.6 million by 2028, registering a CAGR of 4.3% from 2021 to 2028. Rise in incidences of musculoskeletal disorders, development of biocompatible synthetic bone grafts, technological advancements in medical field leading to a shift from autograft to allograft drive the growth of the bone grafts & substitutes market. For instance, as per the data published by World Health Organization (WHO), in 2021, musculoskeletal conditions are the prominent contributors to disability globally, with low back pain being the single primary cause of disability in 160 countries or early deaths. Low back pain causes the greatest burden with a prevalence of 568 million people and this trend is expected to continue for next few years. Bone grafts are implantable materials that promote bone healing through its osteoconductive, osteogenic, and osteoinductive mechanisms. The bone grafts are used in surgical procedures such as spinal fusion surgeries, bone replacement, ensuring new bone formation, and repair of bone fractures. Moreover, bone grafting has applications in the treatment of various bone related disorders such as congenital pseudoarthrosis, dental bone grafting problems, and complex fractures. Allografts, synthetic bone grafts, and demineralized bone matrix are the most commonly used bone grafts worldwide. Download Free Sample of This Strategic Report: https://reportocean.com/industry-verticals/sample-request?report_id=AMR1795 In addition, increase in cases of lifestyle disorders such as diabetes and obesity add to the risk of developing degenerative joint diseases that further fuel the growth of the market. For instance, according to IDF Diabetes Atlas, Ninth Edition 2019, approximately 463 million adults had diabetes and by 2045, the number is estimated to increase to 700 million across the world. Apart from this, more than 1.1 million children were suffering from type 1 diabetes in 2019, which reveals the severity of this disease. Increase in incidences of diabetic cases leading to degenerative joint disorders is expected to provide high market growth and opportunities in near future. On the other hand, high cost of surgeries and ethical issues related with bone grafting procedures restrict the market growth. Conversely, emerging markets, rise in interests of key players toward R&D activities in bone grafts and its substitutes, and increase in demand for orthopedic procedures particularly in geriatric population are expected to provide profitable opportunities for the growth of the market in near future. The research report categorizes the bone graft & substitute market based on product type, application, and region. By product type, it is classified into allografts, bone grafts substitutes, and cell-based matrices. The allografts are further categorized to machined allografts and demineralized bone matrix. The bone graft substitutes segment is further classified into bone morphogenic proteins (BMP) and synthetic bone grafts. By application, it is divided into spinal fusion, trauma, craniomaxilofacial, joint reconstruction, and dental bone grafting. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The healthcare sector is vital to both national economies and people all across the world. One of the industries with the fastest growth rates is this one. There is a correlation between income levels and healthcare spending across nations because healthcare spending accounts for more than 10% of the GDP of the majority of developed countries. According to the Centers for Medicare and Medicaid Services, US healthcare spending increased by 4.6% in 2019 to reach US$ 3.8 trillion, or US$ 11,582 per person and represented 17.7% of GDP. Additionally, households paid for 28.4% of all health expenditures, followed by the federal government for 29.0%. 16.1% of all healthcare costs were paid for by state and municipal governments, while 7.5% came from other private sources. Download Free Sample of This Strategic Report: https://reportocean.com/industry-verticals/sample-request?report_id=AMR1795 Due to advancements spurred by AI/ML, the impact of digital health technology will grow. Data from the Department for Promotion of Industry and Internal Trade show that FDI in the medicines and medication sector totaled US$19.12 billion (DPIIT). KEY BENEFITS FOR STAKEHOLDERS ? The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.? The report provides a quantitative analysis for the period of 2021-2028 to enable stakeholders to capitalize on the prevailing market opportunities.? Extensive analysis of the market based on products helps understand the type of devices used to treat musculoskeletal disorders and degenerative joints diseases.? Competitive intelligence highlights the business practices followed by leading players across various regions.? Comprehensive analysis of all geographic regions helps determine the prevailing opportunities in these regions.? Key market players and their strategies are analysed to understand the competitive outlook of the overall market.? Extensive analysis of the market is conducted by following key product positioning and monitoring the top contenders within the market framework. KEY MARKET PLAYERS– Arthrex, Inc.– Baxter International Inc.– Integra LifeSciences Holdings Corporation– Johnson & Johnson ( DePuy Synthes )– Medtronic Plc.– Musculoskeletal Transplant Foundation– NuVasive, Inc.– Stryker Corporation– Xtant Medical Holdings, Inc.– Zimmer Biomet Holdings, Inc. KEY MARKET SEGMENTSBy Product– Allograftso Machined allograftso Demineralized bone matrix– Bone Grafts Substituteso Bone morphogenic proteins (BMP)o Synthetic bone grafts– Cell based matrices Request To Download Sample of This Strategic Report:- https://reportocean.com/industry-verticals/sample-request?report_id=AMR1795 By Application– Spinal fusion– Trauma– Craniomaxillofacial– Joint reconstruction– Dental bone grafting By Region– North Americao U.S.o Canadao Mexico– Europeo Germanyo Franceo UKo Italyo Spaino Rest of Europe– Asia-Pacifico Japano Chinao Indiao Australiao South Koreao Rest of Asia-Pacific– LAMEAo Brazilo South Africao Saudi Arabiao Rest of LAMEA Table of Content: Report Overview Global Growth Trends Competition Landscape by Key Players Data Segments North America Market Analysis Europe Market Analysis Asia-Pacific Market Analysis Latin America Market Analysis Middle East & Africa Market Analysis Key Players Profiles Market Analysis Analysts Viewpoints/Conclusions Appendix Reasons to Buy This Report: This file will help the peruses with appreciation the opposition interior the ventures and structures for the serious local weather to improve the feasible benefit. The document moreover facilities round the cutthroat scene of the market, and provides exhaustively the piece of the pie, industry positioning, contender organic system, market execution, new

Why You May Be Nauseous After Eating and How to Stop It

Frequently, post-meal nausea is a transient phenomenon that naturally subsides. Nevertheless, should these symptoms endure or intensify, they might signify an underlying issue such as food allergies or a digestive ailment. Addressing the source, one can manage nausea through tailored dietary adjustments, pharmaceutical interventions, or alternative therapies. The pivotal step towards alleviation lies in identifying the root cause behind the nausea. Here, we delve into the potential triggers for post-meal nausea and explore strategies for its prevention and management. What Causes Nausea After Eating? 1. Food Poisoning Foodborne illness can result from consuming food tainted with harmful microorganisms or toxic compounds. Common contributors to foodborne illnesses encompass: 1. Inadequate hand, utensils, and cooking surface hygiene. 2. Prolonged exposure of food to ambient temperatures. 3. Failure to cook food to a sufficiently safe internal temperature. 4. Cross-contamination, where raw meats like chicken or fish come into contact with produce or ready-to-eat items. Signs such as queasiness, emesis, diarrhea, and abdominal spasms usually manifest within half an hour to several hours post-consumption of the contaminated food. These symptoms typically endure for a span of hours to multiple days, typically resolving naturally. 2. Food Allergies or Intolerances Food allergies arise when the immune system recognizes specific foods, like cow’s milk or nuts, as harmful intruders, provoking an exaggerated response that results in the release of histamine and other compounds causing symptoms. These symptoms can manifest within minutes of consumption, encompassing mild nausea, abdominal discomfort, hives, and even breathing difficulties. Prevalent food allergies include: 1. Milk 2. Eggs 3. Soy 4. Peanuts 5. Tree nuts 6. Wheat 7. Shellfish 8. Fish Differing from food allergies, food intolerances lack immune system involvement and instead emerge due to challenges in digesting certain foods or components. These intolerances yield symptoms such as bloating, gas, stomach pain, and diarrhea. A prevalent example of food intolerance is lactose intolerance, wherein the body struggles to process lactose, a sugar present in dairy products. Additional common food intolerances encompass: 1. Gluten 2. Caffeine 3. Histamine, present in foods like wine and cheese 4. Alcohol 5. Sulfites, found in beer, cider, and wine 6. Salicylates, occurring naturally in various fruits, vegetables, and spices 7. Monosodium glutamate (MSG), is prevalent in cured meats and savory dishes. 3. Stomach Virus Viral gastroenteritis, commonly referred to as the “stomach flu,” denotes an intestinal infection triggering symptoms like diarrhea, nausea, vomiting, and abdominal discomfort. In certain instances, it might also induce fever. The principal-agent behind this condition is norovirus, which contributes to the majority of stomach flu cases. Manifestations generally arise within a span of 12 to 48 hours subsequent to exposure and endure for about 3 days. Notably contagious, norovirus rapidly disseminates from person to person. It can be contracted through direct contact, consumption of contaminated food, or contact with virus-laden surfaces followed by touching the mouth. 4. Digestive Diseases Various digestive disorders, encompassing irritable bowel syndrome (IBS), gastroparesis, and gastroesophageal reflux disease (GERD), can contribute to the emergence of post-meal nausea. Here, we delve into prevalent digestive ailments that might give rise to nausea following eating: 1. IBS: A chronic affliction of the digestive system, IBS triggers alterations in bowel patterns, abdominal discomfort, and bloating, despite lacking observable signs of damage or disease within the digestive tract. This condition affects roughly 12% of individuals in the United States. 2. Gastroparesis: Also known as delayed gastric emptying, gastroparesis slows down the passage of food through the stomach. This delay commonly results in early satiety, along with post-meal nausea and vomiting. Diabetes is a frequent cause of gastroparesis. 3. GERD: This condition occurs when stomach contents regurgitate into the esophagus, typically causing heartburn. Nonetheless, it can also lead to nausea among its symptoms. 4. Gallbladder Disease: Chronic gallbladder disorders involve inflammation and the formation of gallstones. These conditions can give rise to gallbladder attacks, often triggered by substantial meals. Gallbladder attacks commonly yield symptoms such as nausea, vomiting, abdominal pain, and fever. 5. Pancreatitis: Characterized by inflammation of the pancreas, pancreatitis is accompanied by abdominal pain, nausea, and vomiting. Gallstones, medications, and excessive alcohol consumption are potential causes of pancreatitis. Medications Certain medications have the potential to induce nausea and alter one’s appetite. This category encompasses: 1. Antibiotics 2. Antidepressants 3. Cancer treatments, notably chemotherapy 4. Pain medications Frequently, the sensation of nausea tends to ameliorate as your body becomes acclimated to the medication or upon discontinuation of the treatment. Pregnancy Pregnancy triggers hormonal shifts that can lead to post-meal nausea. Commonly referred to as morning sickness, this sensation is not confined to mornings and can arise at any hour due to these hormonal fluctuations. Approximately 7 out of 10 pregnant individuals encounter nausea during their initial trimester. While this condition often abates during the second trimester, it can persist throughout the entire pregnancy. Mild instances of morning sickness pose no harm to you or your unborn child. Conversely, severe pregnancy-related nausea and vomiting, known as hyperemesis gravidarum, may necessitate medical intervention. Other Health Condition Additional factors that can lead to post-meal nausea encompass: 1. Diabetes: Nausea might arise when blood sugar levels deviate from the norm, either becoming excessively high or low. Source: American Diabetes Association. Hypoglycemia. 2. Anxiety: Anxiety disorders can contribute to gastrointestinal symptoms, including nausea, following meals. 3. Liver Disease: Initial indications of cirrhosis, characterized by liver scarring, may encompass nausea, vomiting, and reduced appetite. 4. Bowel Obstruction: A situation known as intestinal obstruction transpires when food or stool encounters difficulty in traversing the digestive tract. This blockage is often attributed to factors such as hernias, surgeries, or even cancer. How Can I Get Rid of Nausea After Eating? Here are several strategies to alleviate nausea if you’re experiencing discomfort: 1. Hydration: Maintain your fluid intake with clear liquids to prevent dehydration. 2. Rest: Allow yourself to rest and recuperate, as this can help alleviate the sensation of sickness. 3. Fresh Air: Seek fresh air, as stepping outside or opening a window can provide relief. 4. Ice Cubes: Sucking on ice

The Risks and Benefits of Going Off Antidepressant Medications

A cornerstone in addressing depression lies in the realm of antidepressant therapy. Approximately 7 million adults within the United States are recipients of pharmacological interventions, constituting a key facet of the multifaceted approach to depression management. The efficacy of these medications in alleviating depressive symptoms is evident, yet it’s crucial to remain cognizant of potential ramifications such as side effects and withdrawal phenomena. Noteworthy advantages await those who contemplate the cessation of antidepressant regimens, including financial savings and liberation from adverse effects that might have been experienced. However, prudence dictates that any contemplation of commencing, discontinuing, or modifying the dosage of antidepressants should be conducted under the supervision and guidance of a qualified healthcare professional. Thus, a comprehensive understanding of these therapeutic agents is vital. Delve further into the subject for a deeper comprehension. Possible Benefits of Stopping Antidepressants Antidepressants are formulated with the intent to enhance an individual’s emotional state and address various symptoms linked to depression, such as fatigue and sleep disturbances.2 Furthermore, potential benefits could encompass the avoidance of undesirable side effects and a reduction in concerns regarding the financial implications of medication. Avoidance of Side Effects Varied Responses to Antidepressants: Personalized Side Effect Considerations It’s worth noting that not everyone encounters side effects while undergoing antidepressant treatment.2 However, for those who do, the prospect of discontinuing such medications may hold potential benefits, particularly if it leads to a reduction or alleviation of the experienced side effects. The prevalence of side effects remains a significant factor contributing to the decision to halt antidepressant use. These side effects encompass a wide array, including but not limited to: Moreover, a noteworthy aspect pertains to individuals under the age of 25, encompassing both children and adolescents. This demographic may exhibit a heightened susceptibility to developing suicidal thoughts while undergoing antidepressant treatment. This underscores the significance of careful monitoring and evaluation within this age group. Less Worry About Medication Costs Numerous individuals have shared their intention to discontinue antidepressant usage primarily due to the financial burden associated with these medications. In fact, certain participants in research studies have explicitly cited their inability to sustain their medication regimen owing to financial constraints. An insightful study has revealed a correlation between the practice of shifting or rotating between different antidepressant medications and escalated financial outlays. This implies that the pursuit of optimal antidepressant treatment can potentially incur substantial costs, especially in cases where individuals encounter challenges in identifying an effective medication or encounter delays in accessing the necessary treatment. Hence, understanding the economic aspects intertwined with antidepressant utilization is of paramount importance when evaluating the overall impact of these interventions on individuals’ well-being. What Are the Potential Risks? Choosing not to engage with antidepressant treatment entails certain inherent risks. These risks are closely tied to the possibility of encountering immediate physical manifestations and potential alterations in one’s future mental health trajectory. It’s imperative to acknowledge these potential outcomes when deliberating on the course of action regarding antidepressant therapy. Withdrawal Symptoms Abruptly ceasing or diminishing your prescribed antidepressant regimen can potentially trigger withdrawal symptoms.6 Every type of antidepressant carries the potential for withdrawal symptoms, which tend to intensify and become more pronounced with prolonged usage.7 An integral facet to comprehend is the concept of a medication’s half-life, denoting the time required for a drug’s concentration to decrease by half.8 Withdrawal symptoms can be particularly severe for certain antidepressants due to their specific half-life profiles. Notably, those with shorter half-lives, including MAO inhibitors (MAOIs) like tranylcypromine, certain selective serotonin reuptake inhibitors (SSRIs) like paroxetine, and tricyclic antidepressants (TCAs), have been associated with heightened withdrawal symptoms.9 Termed as “antidepressant discontinuation syndrome,” these withdrawal symptoms collectively encompass various manifestations. Although typically not life-threatening, this syndrome impacts approximately 20% of individuals who discontinue antidepressant use.46 If you find yourself experiencing symptoms such as anxiety, dizziness, fatigue, melancholy, headaches, irritability, nausea, or vomiting, it’s advisable to seek counsel from a healthcare professional promptly. Addressing these concerns with medical guidance ensures a safer and smoother transition. Return of Depressive Symptoms Antidepressants are prescribed with the primary objective of alleviating depressive symptoms. However, ceasing the medication regimen could pave the way for the resurgence of these symptoms. This phenomenon is referred to as relapse, denoting the reappearance of depressive manifestations that had initially been mitigated. It’s important to recognize that withdrawal symptoms may manifest within days of discontinuation, reflecting the body’s adjustment to the absence of the medication. Conversely, the potential for relapse is characterized by a longer timeframe, spanning weeks, months, or even years post-medication cessation. Such variability underscores the complexity of individual responses to antidepressant discontinuation and the subsequent potential for symptom reoccurrence. To ensure informed decision-making and effective management, individuals considering discontinuation should weigh the potential risk of relapse in consultation with a healthcare professional. This collaborative approach aims to strike a balance between the desire for discontinuation and the imperative to maintain psychological well-being. How To Stop Medication Safely Prior to initiating any steps towards discontinuing or minimizing antidepressant usage, it is strongly advisable to seek counsel from a qualified healthcare provider. This professional guidance is paramount, as a healthcare provider can meticulously orchestrate a gradual tapering process to mitigate the risk of withdrawal symptoms.4 Tapering denotes a methodical reduction in the antidepressant dosage over a specific duration. This involves a systematic approach, wherein the prescribed dose is progressively lowered every one to two weeks, typically spanning a four-week period. The tapering regimen may be tailored to account for variables such as the medication’s individual half-life characteristics.11 Following the cessation of medication, it is pivotal to engage with a mental health specialist who can vigilantly monitor your overall well-being. Additionally, these professionals can employ talk therapy as a means to address and manage your depression effectively, fostering a comprehensive and holistic approach to your mental health journey. Why You Should Work With a Healthcare Provider Collaboration with a healthcare provider extends beyond the context of discontinuing antidepressant medications. Seeking professional guidance is equally crucial if you